Explore
New Insights into Antithrombotic Therapy for Cardio- and Cerebrovascular Disease: From Molecular Mechanisms to Clinical Application
0 Ungluers have
Faved this Work
Login to Fave
Thrombosis is a pathophysiological phenomenon observed in acute and chronic coronary syndrome, stroke, and peripheral artery disease. Exposure of the Tissue Factor (TF) to flowing blood is followed to its binding to other coagulation factors leading to thrombin formation. Together with platelet activation, TF ultimately promotes thrombus formation. Recent advances in platelet pathophysiology have shown that these cells are able to regulate their gene/protein expression, engage in de novo protein synthesis, and release different mediators that may interfere with different cell functions. Several clinical trials have clearly shown the efficacy of anticoagulation and/or anti-platelet aggregation in different thrombotic disorders. Real-world practice clearly indicates that antithrombotic strategies need to be personalized according to patient characteristics. The combination of multiple antithrombotic drugs represents a challenging scenario and was the focus of multiple recent randomized controlled trials, with more still to come. As knowledge about platelets and the coagulation system has substantially evolved within the last few years, so should our approach to antithrombotic treatment; focused on current hurdles of antithrombotic treatments in patients with cardio- and cerebrovascular diseases, starting from the molecular mechanisms involved, proposing practical solutions to compelling clinical scenarios using a pathophysiology-oriented approach on the basis of current clinical evidence.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 41 times via unglue.it ebook links.
- 41 - pdf (CC BY) at Unglue.it.
Keywords
- acute coronary syndrome
- acute coronary syndrome (ACS)
- anterior wall myocardial infarction
- anticoagulants
- anticoagulation
- antiplatelet drugs
- antithrombotic therapy
- aspirin
- Atherosclerosis
- Atrial Fibrillation
- atrial fibrillation (AF)
- Cancer
- cangrelor
- cardiotoxicity
- Cardiovascular Diseases
- cardiovascular prevention
- Cerebrovascular disease
- Clinical & internal medicine
- clopidogrel
- coronary artery disease
- Diabetes Mellitus
- direct oral anticoagulants
- dual antiplatelet therapy
- dual antiplatelet therapy (DAPT)
- dual pathway inhibition (DPI)
- dual therapy
- enteric-coated aspirin
- essential thrombocythemia
- factor XI
- factor XI inhibitor
- gastrointestinal bleeding
- hemostasis
- high bleeding risk
- high on-treatment platelet reactivity
- left atrial appendage thrombus
- left ventricular thrombus
- major adverse cardiovascular events (MACE)
- major adverse limb events (MALE)
- matrix metalloproteinase-9
- medicine
- metformin
- monotherapy
- n/a
- new drugs
- novel antithrombotic agents
- oral anticoagulant
- P2Y12 inhibitor
- P2Y12 inhibitors
- Percutaneous coronary intervention
- percutaneous coronary intervention (PCI)
- peripheral artery disease (PAD)
- plaque instability
- platelet function
- prasugrel
- randomized controlled trial
- selatogrel
- Stroke
- surface plasmon resonance
- thema EDItEUR::M Medicine and Nursing
- thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine
- Thrombosis
- thromboxane
- ticagrelor
- triple antithrombotic therapy (TAT)
- zalunfiban
Links
DOI: 10.3390/books978-3-0365-8117-0Editions